专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009064497A1 PROSTATIC ACID PHOSPHATASE FOR THE TREATMENT OF PAIN 审中-公开
标题翻译：用于治疗疼痛的前列腺酸磷酸酯酶
公开(公告)号：WO2009064497A1
公开(公告)日：2009-05-22
申请号：PCT/US2008/012849
申请日：2008-11-17
申请人： THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL , VIHKO, Pirkko , ZYLKA, Mark
发明人： VIHKO, Pirkko , ZYLKA, Mark
IPC分类号： A61K38/57 , A61P29/00
CPC分类号： A61K38/465 , A61K9/0019 , A61K31/485 , A61K38/57 , A61K45/06 , C12Q1/42 , C12Q1/6883 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , G01N2500/04 , Y10T436/143333 , A61K2300/00
摘要： Methods and compositions are provided for the treatment of pain and cystic fibrosis. The methods include administering to an animal a composition or a pharmaceutical formulation comprising a therapeutically effective amount of a Prostatic Acid Phosphatase ("PAP") polypeptide, or an active variant, fragment or derivative thereof, or a therapeutically effective amount of an activity enhancing PAP modulator. PAP is provided as a treatment for chronic pain including neuropathic and inflammatory pain in animals and humans. The PAP, or the active variant, fragment or derivative thereof, or the activity enhancing modulator of the PAP is administered via one or more of injection, intrathecal injection, oral administration, a surgically implanted pump, stem cells, viral gene therapy, or naked DNA gene therapy. Intrathecal injection of PAP functions as an analgesic and reduces thermal sensitivity in mice. PAP can reduce chronic mechanical and thermal inflammatory pain in mice. Allodynia and hyperalgesia due to nerve injury can be prevented by increasing PAP activity in spinal cord.
摘要翻译：提供方法和组合物用于治疗疼痛和囊性纤维化。所述方法包括向动物施用包含治疗有效量的前列腺酸性磷酸酶（“PAP”）多肽或其活性变体，片段或衍生物或治疗有效量的活性增强PAP的组合物或药物制剂调制器。 PAP作为慢性疼痛的治疗方法，包括动物和人类的神经性和炎性疼痛。通过注射，鞘内注射，口服给药，手术植入的泵，干细胞，病毒基因治疗或裸体的PAP或其活性变体片段或衍生物或PAP的活性增强调节剂 DNA基因治疗。鞘内注射PAP作为镇痛剂，降低小鼠的热敏感性。 PAP可以减少小鼠的慢性机械和热炎性疼痛。通过增加脊髓中的PAP活性可以预防由于神经损伤引起的异常性疼痛和痛觉过敏。

2. 发明公开

EP2219666A1 PROSTATIC ACID PHOSPHATASE FOR THE TREATMENT OF PAIN 审中-公开
标题翻译：前列腺酸性磷酸酶在疼痛的治疗
公开(公告)号：EP2219666A1
公开(公告)日：2010-08-25
申请号：EP08851001.1
申请日：2008-11-17
申请人： The University of North Carolina At Chapel Hill , Vihko, Pirkko
发明人： VIHKO, Pirkko , ZYLKA, Mark
IPC分类号： A61K38/57 , A61P29/00
CPC分类号： A61K38/465 , A61K9/0019 , A61K31/485 , A61K38/57 , A61K45/06 , C12Q1/42 , C12Q1/6883 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , G01N2500/04 , Y10T436/143333 , A61K2300/00
摘要： Methods and compositions are provided for the treatment of pain and cystic fibrosis. The methods include administering to an animal a composition or a pharmaceutical formulation comprising a therapeutically effective amount of a Prostatic Acid Phosphatase ('PAP') polypeptide, or an active variant, fragment or derivative thereof, or a therapeutically effective amount of an activity enhancing PAP modulator. PAP is provided as a treatment for chronic pain including neuropathic and inflammatory pain in animals and humans. The PAP, or the active variant, fragment or derivative thereof, or the activity enhancing modulator of the PAP is administered via one or more of injection, intrathecal injection, oral administration, a surgically implanted pump, stem cells, viral gene therapy, or naked DNA gene therapy. Intrathecal injection of PAP functions as an analgesic and reduces thermal sensitivity in mice. PAP can reduce chronic mechanical and thermal inflammatory pain in mice. Allodynia and hyperalgesia due to nerve injury can be prevented by increasing PAP activity in spinal cord.

3. 发明申请

WO2004080271A3 METHOD FOR PROGNOSTICATING THE PROGRESS OF BREAST CANCER AND COMPOUNDS USEFUL FOR PREVENTION OR TREATMENT THEREOF 审中-公开
公开(公告)号：WO2004080271A3
公开(公告)日：2004-09-23
申请号：PCT/FI2004/000145
申请日：2004-03-12
申请人： VIHKO, Pirkko , ISOMAA, Veli
发明人： VIHKO, Pirkko , ISOMAA, Veli
IPC分类号： A61K31/519
摘要： This invention concerns in vitro method for prognosticating the progress of breast cancer, comprising detecting or quantifying the level of 17β-hydroxysteroid dehydrogenase (17HSD) type 1 enzyme in breast tumor tissue sample, wherein the presence of said 17HSD type 1 enzyme is indicative of severe progress of breast cancer. Furthermore, the invention also concerns the use of a 17HSD type 1 enzyme inhibitor for prevention or treatment of breast cancer. This invention concerns also the use of compound A in the manufacture of a pharmaceutically acceptable preparation useful as 17HSD inhibitor.

4. 发明申请

WO2008155467A1 TRANSMEMBRANE PROSTATIC ACID PHOSPHATASE 审中-公开
标题翻译：转运蛋白磷酸化磷酸酶
公开(公告)号：WO2008155467A1
公开(公告)日：2008-12-24
申请号：PCT/FI2008/050377
申请日：2008-06-19
申请人： CHEMPATH OY , VIHKO, Pirkko
发明人： VIHKO, Pirkko
IPC分类号： A61K38/46 , C12N9/16 , G01N33/574 , C40B30/06 , A61P3/00 , A61P35/00
CPC分类号： C12Y301/03002 , A61K38/465 , A61K47/64 , G01N2333/916
摘要： The present invention relates to a novel transmembrane prostatic acid phosphatase (TM-PAP) protein or the C-terminal part thereof, nucleic acid molecules encoding said protein, vectors containing said nucleic acid molecules and host cells expressing said proteins. The present invention relates also to pharmaceutical compositions containing TM-PAP or the C-terminal part thereof and methods for using thereof in therapy and diagnostics. The present invention also relates to methods utilizing a transmembrane prostatic acid phosphatase knockout/knockdown non-human animal model and uses thereof.
摘要翻译：本发明涉及新型跨膜前列腺酸性磷酸酶（TM-PAP）蛋白或其C-末端部分，编码所述蛋白质的核酸分子，含有所述核酸分子的载体和表达所述蛋白质的宿主细胞。本发明还涉及含有TM-PAP或其C-末端部分的药物组合物及其在治疗和诊断中的应用。本发明还涉及利用跨膜前列腺酸性磷酸酶敲除/敲低非人动物模型及其用途的方法。

5. 发明申请

WO2006051172A1 METHOD FOR TESTING A COMPOUND FOR A THERAPEUTIC EFFECT AND A DIAGNOSTIC METHOD 审中-公开
标题翻译：用于测试治疗效果和诊断方法的化合物的方法
公开(公告)号：WO2006051172A1
公开(公告)日：2006-05-18
申请号：PCT/FI2005/050417
申请日：2005-11-11
申请人： CHEMPATH OY , VIHKO, Pirkko
发明人： VIHKO, Pirkko
IPC分类号： C12Q1/42 , G01N33/50 , C40B30/06 , A01K67/027
CPC分类号： G01N33/5044 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/0331 , C12N9/16 , C12N15/8509 , C12Q1/42 , G01N33/5008 , G01N33/5011 , G01N33/5041 , G01N33/5058 , G01N33/5061 , G01N33/507 , G01N33/5091 , G01N2500/00 , Y10T436/163333
摘要： This invention relates to a method for testing compound for a therapeutic effect utilizing a non-human animal or cell having disruption in the prostatic acid phosphatase gene resulting in a decrease or absence in the activity or the level of prostatic acid phosphatase. Said compound may be used for treating disorders related to unbalanced phosphatidylinositol phosphate cascade or signaling pathway. The invention relates also to diagnostic methods and methods for treating said disorders with therapeutic compounds or by gene therapy.
摘要翻译：本发明涉及使用导致前列腺酸性磷酸酶基因破坏的非人动物或细胞的治疗效果来测试化合物的方法，导致前列腺酸性磷酸酶的活性或水平的降低或降低。所述化合物可用于治疗与不平衡磷脂酰肌醇磷酸级联或信号通路相关的病症。本发明还涉及用治疗化合物或通过基因治疗来治疗所述疾病的诊断方法和方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式